vs
BioAge Labs, Inc.（BIOA）与Rithm Property Trust Inc.（RPT）财务数据对比。点击上方公司名可切换其他公司
Rithm Property Trust Inc.的季度营收约是BioAge Labs, Inc.的1.1倍（$3.4M vs $3.1M），Rithm Property Trust Inc.净利率更高（95.4% vs -842.9%，领先938.2%）
Altos Labs是一家美国生物技术研究企业，主营业务为开发可延缓或逆转人类衰老进程的寿命延长疗法，围绕该方向开发基于诱导多能干细胞的专用细胞疗法。该公司由俄罗斯裔科技企业家尤里·米尔纳，以及杰夫·贝佐斯等投资人于2021年出资成立，2022年正式启动运营。
Rithm Property Trust Inc.旗下的里思资本是一家总部位于纽约的美国投资管理公司，核心业务聚焦于房地产投资及另类投资领域，是该赛道颇具影响力的专业投资机构。
BIOA vs RPT — 直观对比
营收规模更大
RPT
是对方的1.1倍
$3.1M
净利率更高
RPT
高出938.2%
-842.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $3.1M | $3.4M |
| 净利润 | $-25.9M | $3.2M |
| 毛利率 | — | — |
| 营业利润率 | -923.4% | 99.6% |
| 净利率 | -842.9% | 95.4% |
| 营收同比 | — | -39.7% |
| 净利润同比 | — | 11.2% |
| 每股收益（稀释后） | $-0.72 | $-0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIOARPT
| Q4 25 | $3.1M | $3.4M | ||
| Q3 25 | $2.1M | $4.0M | ||
| Q2 25 | $2.4M | $4.2M | ||
| Q1 25 | $1.5M | $249.0K | ||
| Q3 24 | $0 | — | ||
| Q3 23 | — | $1.1M | ||
| Q1 23 | — | $540.0K | ||
| Q4 22 | — | $1.4M |
净利润BIOARPT
| Q4 25 | $-25.9M | $3.2M | ||
| Q3 25 | $-20.2M | $-273.0K | ||
| Q2 25 | $-21.6M | $1.9M | ||
| Q1 25 | $-12.9M | $-3.4M | ||
| Q3 24 | $-23.4M | — | ||
| Q3 23 | — | $-5.5M | ||
| Q1 23 | — | $-7.4M | ||
| Q4 22 | — | — |
营业利润率BIOARPT
| Q4 25 | -923.4% | 99.6% | ||
| Q3 25 | -1126.6% | -6.2% | ||
| Q2 25 | -1027.0% | 45.7% | ||
| Q1 25 | -1133.4% | -1416.5% | ||
| Q3 24 | — | — | ||
| Q3 23 | — | -533.4% | ||
| Q1 23 | — | -1346.5% | ||
| Q4 22 | — | — |
净利率BIOARPT
| Q4 25 | -842.9% | 95.4% | ||
| Q3 25 | -982.0% | -6.8% | ||
| Q2 25 | -894.0% | 45.1% | ||
| Q1 25 | -891.0% | -1363.1% | ||
| Q3 24 | — | — | ||
| Q3 23 | — | -526.3% | ||
| Q1 23 | — | -1369.3% | ||
| Q4 22 | — | — |
每股收益（稀释后）BIOARPT
| Q4 25 | $-0.72 | $-0.26 | ||
| Q3 25 | $-0.56 | $-0.03 | ||
| Q2 25 | $-0.60 | $0.01 | ||
| Q1 25 | $-0.36 | $-0.08 | ||
| Q3 24 | $-6.70 | — | ||
| Q3 23 | — | $-0.25 | ||
| Q1 23 | — | $-0.34 | ||
| Q4 22 | — | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $281.1M | $79.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $272.1M | $291.6M |
| 总资产 | $294.9M | $1.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BIOARPT
| Q4 25 | $281.1M | $79.3M | ||
| Q3 25 | $285.8M | $81.4M | ||
| Q2 25 | $297.3M | $98.6M | ||
| Q1 25 | $320.5M | $97.4M | ||
| Q3 24 | $334.5M | — | ||
| Q3 23 | — | $63.9M | ||
| Q1 23 | — | $49.4M | ||
| Q4 22 | — | $47.8M |
总债务BIOARPT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $7.1M | — | ||
| Q3 24 | $9.9M | — | ||
| Q3 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — |
股东权益BIOARPT
| Q4 25 | $272.1M | $291.6M | ||
| Q3 25 | $277.5M | $291.7M | ||
| Q2 25 | $294.8M | $294.7M | ||
| Q1 25 | $313.2M | $296.1M | ||
| Q3 24 | $313.7M | — | ||
| Q3 23 | — | $320.2M | ||
| Q1 23 | — | $330.4M | ||
| Q4 22 | — | $335.3M |
总资产BIOARPT
| Q4 25 | $294.9M | $1.0B | ||
| Q3 25 | $305.1M | $1.0B | ||
| Q2 25 | $322.1M | $1.0B | ||
| Q1 25 | $343.8M | $1.0B | ||
| Q3 24 | $337.4M | — | ||
| Q3 23 | — | $1.4B | ||
| Q1 23 | — | $1.4B | ||
| Q4 22 | — | $1.5B |
负债/权益比BIOARPT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.02× | — | ||
| Q3 24 | 0.03× | — | ||
| Q3 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-28.3M | $-8.3M |
| 自由现金流经营现金流 - 资本支出 | $-28.4M | — |
| 自由现金流率自由现金流/营收 | -921.5% | — |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | -2.56× |
| 过去12个月自由现金流最近4个季度 | $-82.3M | — |
8季度趋势，按日历期对齐
经营现金流BIOARPT
| Q4 25 | $-28.3M | $-8.3M | ||
| Q3 25 | $-16.0M | $-5.8M | ||
| Q2 25 | $-20.0M | $-25.0K | ||
| Q1 25 | $-17.4M | $-1.6M | ||
| Q3 24 | — | — | ||
| Q3 23 | — | $-10.7M | ||
| Q1 23 | — | $-16.8M | ||
| Q4 22 | — | $1.1M |
自由现金流BIOARPT
| Q4 25 | $-28.4M | — | ||
| Q3 25 | $-16.1M | — | ||
| Q2 25 | $-20.1M | — | ||
| Q1 25 | $-17.8M | — | ||
| Q3 24 | — | — | ||
| Q3 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | $1.1M |
自由现金流率BIOARPT
| Q4 25 | -921.5% | — | ||
| Q3 25 | -782.2% | — | ||
| Q2 25 | -834.5% | — | ||
| Q1 25 | -1226.0% | — | ||
| Q3 24 | — | — | ||
| Q3 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | 80.6% |
资本支出强度BIOARPT
| Q4 25 | 3.6% | — | ||
| Q3 25 | 1.1% | — | ||
| Q2 25 | 6.6% | — | ||
| Q1 25 | 29.4% | — | ||
| Q3 24 | — | — | ||
| Q3 23 | — | 0.0% | ||
| Q1 23 | — | — | ||
| Q4 22 | — | 2.0% |
现金转化率BIOARPT
| Q4 25 | — | -2.56× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.01× | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q3 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
